- Home
- NMZ vs IMTX Comparison
NMZ vs IMTX Comparison
Compare NMZ & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMZ | IMTX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMZ | IMTX |
|---|---|---|
| Price | $10.29 | $9.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 451.1K | ★ 509.0K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.36 | $3.30 |
| 52 Week High | $11.04 | $12.41 |
Technical Indicators
Market Signals| Indicator | NMZ | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 52.19 |
| Support Level | $10.21 | $9.71 |
| Resistance Level | $10.40 | $10.64 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 59.62 | 64.70 |
Price Performance
Historical ComparisonAbout NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income exempt from regular federal income tax. The Fund's secondary investment objective is to seek an attractive total return consistent with its primary objective.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.